search
Back to results

Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

Primary Purpose

Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Garmin Vivofit Activity Tracker
Sponsored by
NRG Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Non-small Cell Lung Cancer focused on measuring Locally advanced non-small cell lung cancer, LA-NSCLC, Activity Tracking

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of NSCLC
  • Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include:

    • Definitive treatment of stage III disease (most common)
    • Definitive treatment for locoregional recurrence of early stage disease
    • Definitive treatment of unresectable stage II disease
    • Preoperative treatment of stage III disease
    • Postoperative treatment after incomplete resection (uncommon)
    • Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy)
  • ECOG Performance Status 0-3 within 30 days prior to registration
  • Age ≥ 18
  • Ambulates independently or with a cane (use of a walker not permitted)
  • Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study.
  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry.

Exclusion Criteria:

  • Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC
  • Patients receiving concurrent treatment for another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy
  • Patients receiving thoracic radiotherapy without concurrent chemotherapy are ineligible. Patients receiving concurrent chemotherapy and another form of systemic therapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy with concurrent immunotherapy or targeted therapy but without chemotherapy are ineligible

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Arm I: Usual Care

    Arm II: Usual Care + Continuous physical activity monitoring via a wearable device

    Arm Description

    Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.

    Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.

    Outcomes

    Primary Outcome Measures

    Occurrence of hospital admission
    Occurrence of hospital admission during radiation treatment or within 1 month after radiotherapy completion.
    Occurrence of emergency room visit lasting more than 24 hours
    Occurrence of emergency room visit lasting more than 24 hours during radiation treatment or within 1 month after radiotherapy completion.
    Occurrence of radiation treatment interruption
    Occurrence of of radiation treatment interruption (missing two or more treatments, not due to machine issues or scheduled holidays) during radiation treatment.

    Secondary Outcome Measures

    Full Information

    First Posted
    April 30, 2021
    Last Updated
    August 1, 2023
    Sponsor
    NRG Oncology
    Collaborators
    Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program (PA CURE)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04878952
    Brief Title
    Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
    Official Title
    Activity Monitoring to Improve Patient Care During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 29, 2023 (Anticipated)
    Primary Completion Date
    July 10, 2024 (Anticipated)
    Study Completion Date
    July 10, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    NRG Oncology
    Collaborators
    Pennsylvania Department of Health Commonwealth Universal Research Enhancement Program (PA CURE)

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.
    Detailed Description
    PRIMARY OBJECTIVE: To demonstrate that monitoring daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse clinical events during the radiotherapy course. SECONDARY OBJECTIVES: I. To demonstrate the feasibility of monitoring daily step counts during a course of chemoradiotherapy in the setting of a multi-institutional trial. II. To examine the association between baseline activity level and clinical outcomes related to treatment tolerance, quality of life, chemoradiotherapy adverse events, and physical function preservation. III. To demonstrate associations between daily step counts and short-term hospitalization risk. IV. To explore predictors of step count decline during chemoradiotherapy among clinical factors and radiotherapy plan parameters. EXPLORATORY OBJECTIVES: I. To explore patterns of care regarding adjuvant immunotherapy administration following definitive chemoradiotherapy for locally advanced non-small cell lung cancer. II. To examine the association between baseline activity level with progression free survival and overall survival. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Usual Care ARM II: Usual Care + Continuous physical activity monitoring via a wearable device. Patients randomized to undergo activity monitoring will use a wearable device from the time of study enrollment until four weeks after the completion of thoracic radiotherapy.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Recurrent Non Small Cell Lung Cancer
    Keywords
    Locally advanced non-small cell lung cancer, LA-NSCLC, Activity Tracking

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    144 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Arm I: Usual Care
    Arm Type
    No Intervention
    Arm Description
    Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy.
    Arm Title
    Arm II: Usual Care + Continuous physical activity monitoring via a wearable device
    Arm Type
    Experimental
    Arm Description
    Patients will receive their usual care of thoracic radiotherapy with concurrent chemotherapy along with continuous physical activity monitoring via a wearable device.
    Intervention Type
    Other
    Intervention Name(s)
    Garmin Vivofit Activity Tracker
    Intervention Description
    Activity tracker that is worn on the wrist.
    Primary Outcome Measure Information:
    Title
    Occurrence of hospital admission
    Description
    Occurrence of hospital admission during radiation treatment or within 1 month after radiotherapy completion.
    Time Frame
    From study enrollment to 1 month after radiotherapy completion.
    Title
    Occurrence of emergency room visit lasting more than 24 hours
    Description
    Occurrence of emergency room visit lasting more than 24 hours during radiation treatment or within 1 month after radiotherapy completion.
    Time Frame
    From study enrollment to 1 month after radiotherapy completion.
    Title
    Occurrence of radiation treatment interruption
    Description
    Occurrence of of radiation treatment interruption (missing two or more treatments, not due to machine issues or scheduled holidays) during radiation treatment.
    Time Frame
    From study enrollment to radiotherapy completion.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Pathologically (histologically or cytologically) proven diagnosis of NSCLC Planned initiation (within the 30 days after study registration) of fractionated (≥15 treatments) thoracic radiotherapy with concurrent chemotherapy. Expected treatment scenarios include: Definitive treatment of stage III disease (most common) Definitive treatment for locoregional recurrence of early stage disease Definitive treatment of unresectable stage II disease Preoperative treatment of stage III disease Postoperative treatment after incomplete resection (uncommon) Radical treatment for a patient with advanced/metastatic disease with the goal of achieving long-term thoracic disease control (e.g., oligometastatic disease where metastases are addressed with resection or stereotactic radiotherapy) ECOG Performance Status 0-3 within 30 days prior to registration Age ≥ 18 Ambulates independently or with a cane (use of a walker not permitted) Patients who already use wearable devices and/or smartphones that monitor physical activity are eligible for this trial. Patients must agree to wear the device provided by the study. The patient or a legally authorized representative must provide study-specific informed consent prior to study entry. Exclusion Criteria: Patients with a history of another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy for NSCLC Patients receiving concurrent treatment for another cancer that is expected to affect the toxicity profile of thoracic chemoradiotherapy Patients receiving thoracic radiotherapy without concurrent chemotherapy are ineligible. Patients receiving concurrent chemotherapy and another form of systemic therapy (e.g., immunotherapy) are eligible. Patients receiving radiotherapy with concurrent immunotherapy or targeted therapy but without chemotherapy are ineligible
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Nitin Ohri, MD
    Phone
    718-920-7750
    Email
    nitin.ohri@einsteinmed.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nitin Ohri, MD
    Organizational Affiliation
    NRG Oncology
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer

    We'll reach out to this number within 24 hrs